Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Rosenbauer, Marinomed (19/02/2021)

21.02.2021

Rosenbauer: In 2020, the Rosenbauer Group, world’s leading manufacturer of systems for firefighting and disaster
protection, successfully overcame the restrictions imposed by the COVID-19 pandemic and once again achieved a record year. Both revenues and EBIT reached historic highs of Euro 1,041.3 mn (2019: Euro 978.1 mn) and Euro 57.0 mn (2019: Euro 51.9 mn) respectively. The financial result was at the level of the previous year, with lower shares of joint ventures being offset by likewise lower interest expenses. Earnings before taxes (EBT) therefore amounted to Euro 50.5 mn (2019: Euro 45.5 mn). In the past year, the Rosenbauer Group reported solid incoming orders of Euro 1,007.7 mn (2019: Euro 1,073.0 mn). Orders in the CEEU (Central and Eastern Europe) and NOMA (North and Central America) sales regions in particular increased, as did the Stationary Fire Protection segment. In the US, for example, almost ten initial orders were received for the Revolutionary Technology (RT) – the first Rosenbauer firefighting vehicle with an alternative drive system. The MENA area was stable compared with 2019. At Euro 1,072.1 mn as of December 31, 2020 (2019: Euro 1,149.5 mn), the order backlog was on a par with consolidated annual revenue. Based on this solid order backlog, Rosenbauer’s Executive Board expects stable revenues and, once again, an EBIT margin in the region of 5% for 2021. Possible business disruptions due to the COVID-19 pandemic do not allow for a more precise forecast at this point in time.
Rosenbauer: weekly performance: 2.39%

Marinomed: Marinomed Biotech announces that a nasal spray with iota-carrageenan, which is identical to Marinomed’s Carragelose®, showed significant efficacy in the prevention of COVID-19 in hospital staff who manage patients with this disease. These were the results of an independent and investigator-initiated study conducted by an Argentinian research group. In the multicenter, randomized, double-blind, controlled CARR-COV-02 study, 394 healthcare staff were randomly assigned to receive iota-carrageenan nasal spray (N = 199) or placebo (N = 195) four times per day. Both groups had similar gender and age distributions.
Marinomed Biotech: weekly performance: 17.65%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (19/02/2021)


Partners









latest 21st Austria

21st Austria weekly - Rosenbauer, Marinomed (19/02/2021)


21.02.2021, 2312 Zeichen



Rosenbauer: In 2020, the Rosenbauer Group, world’s leading manufacturer of systems for firefighting and disaster
protection, successfully overcame the restrictions imposed by the COVID-19 pandemic and once again achieved a record year. Both revenues and EBIT reached historic highs of Euro 1,041.3 mn (2019: Euro 978.1 mn) and Euro 57.0 mn (2019: Euro 51.9 mn) respectively. The financial result was at the level of the previous year, with lower shares of joint ventures being offset by likewise lower interest expenses. Earnings before taxes (EBT) therefore amounted to Euro 50.5 mn (2019: Euro 45.5 mn). In the past year, the Rosenbauer Group reported solid incoming orders of Euro 1,007.7 mn (2019: Euro 1,073.0 mn). Orders in the CEEU (Central and Eastern Europe) and NOMA (North and Central America) sales regions in particular increased, as did the Stationary Fire Protection segment. In the US, for example, almost ten initial orders were received for the Revolutionary Technology (RT) – the first Rosenbauer firefighting vehicle with an alternative drive system. The MENA area was stable compared with 2019. At Euro 1,072.1 mn as of December 31, 2020 (2019: Euro 1,149.5 mn), the order backlog was on a par with consolidated annual revenue. Based on this solid order backlog, Rosenbauer’s Executive Board expects stable revenues and, once again, an EBIT margin in the region of 5% for 2021. Possible business disruptions due to the COVID-19 pandemic do not allow for a more precise forecast at this point in time.
Rosenbauer: weekly performance: 2.39%

Marinomed: Marinomed Biotech announces that a nasal spray with iota-carrageenan, which is identical to Marinomed’s Carragelose®, showed significant efficacy in the prevention of COVID-19 in hospital staff who manage patients with this disease. These were the results of an independent and investigator-initiated study conducted by an Argentinian research group. In the multicenter, randomized, double-blind, controlled CARR-COV-02 study, 394 healthcare staff were randomly assigned to receive iota-carrageenan nasal spray (N = 199) or placebo (N = 195) four times per day. Both groups had similar gender and age distributions.
Marinomed Biotech: weekly performance: 17.65%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (19/02/2021)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #619: Neuer bei Addiko, dad.at mit Milestone und grossem Neukundenpaket, alle Details Börsentag Wien 4.6.




 

Bildnachweis

Aktien auf dem Radar:Addiko Bank, Strabag, CA Immo, Flughafen Wien, Austriacard Holdings AG, Marinomed Biotech, ATX TR, S Immo, Porr, AT&S, Rosgix, RBI, Uniqa, ams-Osram, Cleen Energy, DO&CO, FACC, Lenzing, Oberbank AG Stamm, Agrana, Amag, Erste Group, EVN, Immofinanz, Österreichische Post, Polytec Group, Telekom Austria, VIG, Wienerberger, Zumtobel, Airbus Group.


Random Partner

AT&S
Austria Technologie & Systemtechnik AG (AT&S) ist europäischer Marktführer und weltweit einer der führenden Hersteller von Leiterplatten und IC-Substraten. Mit 9.526 Mitarbeitern entwickelt und produziert AT&S an sechs Produktionsstandorten in Österreich, Indien, China und Korea und ist mit einem Vertriebsnetzwerk in Europa, Asien und Nordamerika präsent. (Stand 06/17)

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten